In recent years, the incidence of colorectal cancer (CRC) and breast cancer (BC) has increased worldwide and caused a higher mortality rate due to the lack of selective anti-tumor therapies. Current chemotherapies and surgical interventions are significantly preferred modalities to treat CRC or BC in advanced stages but the prognosis for patients with advanced CRC and BC remains dismal. The immunotherapy technique of chimeric antigen receptor (CAR)-T cells has resulted in significant clinical outcomes when treating hematologic malignancies. The novel CAR-T therapy target antigens include GUCY2C, CLEC14A, CD26, TEM8/ANTXR1, PDPN, PTK7, PODXL, CD44, CD19, CD20, CD22, BCMA, GD2, Mesothelin, TAG-72, CEA, EGFR, B7H3, HER2, IL13Ra2, MUC1, EpCAM, PSMA, PSCA, NKG2D. The significant aim of this review is to explore the recently updated information pertinent to several novel targets of CAR-T for CRC, and BC. We vividly described the challenges of CAR-T therapies when treating CRC or BC. The immunosuppressive microenvironment of solid tumors, the shortage of tumor-specific antigens, and post-treatment side effects are the major hindrances to promoting the development of CAR-T cells. Several clinical trials related to CAR-T immunotherapy against CRC or BC have already been in progress. This review benefits academicians, clinicians, and clinical oncologists to explore more about the novel CAR-T targets and overcome the challenges during this therapy.

近年来，由于缺乏选择性抗肿瘤治疗，结直肠癌（CRC）和乳腺癌（BC）的发病率在全球范围内不断增加，并导致较高的死亡率。目前化疗和手术干预是治疗晚期 CRC 或 BC 的首选方式，但晚期 CRC 和 BC 患者的预后仍然不佳。嵌合抗原受体（CAR）-T 细胞的免疫治疗技术在治疗血液恶性肿瘤时取得了显着的临床效果。新型CAR-T疗法靶抗原包括GUCY2C、CLEC14A、CD26、TEM8/ANTXR1、PDPN、PTK7、PODXL、CD44、CD19、CD20、CD22、BCMA、GD2、间皮素、TAG-72、CEA、EGFR、B7H3、HER2 、IL13Ra2、MUC1、EpCAM、PSMA、PSCA、NKG2D。本次综述的重要目的是探索与 CRC 和 BC 的 CAR-T 几个新靶点相关的最新信息。我们生动地描述了 CAR-T 疗法在治疗 CRC 或 BC 时面临的挑战。实体瘤的免疫抑制微环境、肿瘤特异性抗原的缺乏以及治疗后的副作用是促进CAR-T细胞发展的主要障碍。多项针对 CRC 或 BC 的 CAR-T 免疫疗法相关临床试验已经在进行中。本次综述有利于院士、临床医生和临床肿瘤学家进一步探索新型 CAR-T 靶点并克服治疗过程中的挑战。